Literature DB >> 11311759

Antiphospholipid syndrome and recurrent miscarriages.

D Vinatier1, P Dufour, M Cosson, J L Houpeau.   

Abstract

Sixty percent of recurrent spontaneous abortions are unexplained. Antiphospholipid syndrome is a multisystem disease with the predominant features of venous and arterial thrombosis, recurrent pregnancy loss, foetal death and the presence of antiphospholipid antibodies. Many epidemiological studies focus on antiphospholipid autoantibodies syndrome (APS) as a cause of recurrent spontaneous abortion (RSA). It is found that 7-25% of RSA would have APS as the main risk factor. 'Association not being synonymous with cause', the proportion of abortions due to the APS is difficult to estimate for several reasons: definition of recurrent abortion is variable, the assays for antiphospholipid antibodies are not well standardised, inclusion of patients in the study group according to the antibodies titre is author dependent. Recent studies suggest association of antiphospholipid antibodies syndrome not only with recurrent abortions but also with infertility. New mechanisms are described by which antiphospholipid antibodies could cause placental thrombosis and infarction, acting directly on the surface anticoagulant expressed on trophoblastic cells. Only lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) assays are sufficiently standardised to be usable in routine. Testing for other antiphospholipid antibodies (aPLs) should remain investigational. Several treatments have been proposed: low doses of aspirin, low or immunosuppressive doses of corticosteroids, and preventive or effective dose of heparin, intravenous immunoglobulin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311759     DOI: 10.1016/s0301-2115(00)00404-8

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  16 in total

Review 1.  Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease.

Authors:  M Ángeles Martínez-Zamora; Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  The haplotype M2 of the ANXA5 gene is not associated with antitrophoblast antibodies.

Authors:  Nina Rogenhofer; Laura Engels; Nadja Bogdanova; Frank Tüttelmann; Arseni Markoff; Christian J Thaler
Journal:  J Assist Reprod Genet       Date:  2013-03-27       Impact factor: 3.412

Review 3.  Lantibiotics as probes for phosphatidylethanolamine.

Authors:  Ming Zhao
Journal:  Amino Acids       Date:  2009-11-22       Impact factor: 3.520

4.  The prevalence of positive serum anticardiolipin antibodies and asymptomatic bacteriuria in women with recurrent abortions.

Authors:  Zakarea Abdullah Yaseen Al-Khayat; Nabeel Elia Waheda; Nabaz Faisal Shaker
Journal:  Eurasian J Med       Date:  2013-02

5.  Phosphatidylethanolamine at the luminal endothelial surface--implications for hemostasis and thrombotic autoimmunity.

Authors:  Clive W Wells; Paula E North; Suresh Kumar; Christine B Duris; John A McIntyre
Journal:  Clin Appl Thromb Hemost       Date:  2009-11-10       Impact factor: 2.389

Review 6.  Livedo reticularis as a criterion for antiphospholipid syndrome.

Authors:  E Toubi; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 7.  Antiphospholipid antibodies in pediatrics.

Authors:  Ana I Quintero-Del-Rio
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

8.  Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss.

Authors:  C Bu; C Zhang; Z Li; L Gao; Z Xie; G Cai
Journal:  Clin Exp Immunol       Date:  2007-04-11       Impact factor: 4.330

Review 9.  Chronic Inflammatory Placental Disorders Associated With Recurrent Adverse Pregnancy Outcome.

Authors:  Emily F Cornish; Thomas McDonnell; David J Williams
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

10.  Catastrophic antiphospholipid syndrome related to severe ovarian hyperstimulation.

Authors:  V Giner; M R Oltra; M J Esteban; M J García-Fuster; A Salvador; J Núñez; J Redón
Journal:  Clin Rheumatol       Date:  2006-03-15       Impact factor: 3.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.